Abstract 3786
Background
Neuroendocrine system plays a critical role in regulating the immune system, and therefore the progression and prognosis of pancreatic neuroendocrine tumors (pNETs) may be largely influenced and reflected by immune cell levels. Lymphocytes are crucial immune cells that correlate with tumorigenesis and tumor progression, and lymphocyte subsets in peripheral blood, which include CD4+ and CD8+ T cells, B cells and NK cells, are reported to reflect tumor prognosis and progression in various cancer types. We thus speculated that peripheral lymphocyte subset proportion may reflect the state of progression and predict tumor prognosis of pNETs.
Methods
A retrospective, follow-up cohort study consisting 73 patients diagnosed as pNETs was conducted. Flow cytometry was performed to analyze peripheral lymphocyte subsets. Ultivariate analyses were performed using the stepwise Cox hazards model, and Kaplane-Meier methods and log-rank tests were used for the comparison of survival rates, Mann-Whitney U test were used for analyses of the correlation between lymphocyte subset percentage and clinicopathologic parameters.
Results
pNET patients with distant metastasis were associated with lower CD3+ T cell (p = 0.003), lower CD4+ T cell (p = 0.006) and higher NK cell (p = 0.003) percentage in peripheral blood. Lower percentage of CD3+, CD4+ T cells, B cells and higher percentage of NK cells in peripheral blood were associated with shorter progression-free survival (PFS). Distant metastasis (HR = 29.194, 95%CI: 6.865 to 124.144 p < 0.001) and lower percentage peripheral B cells turned out to be independent risk factors for PFS both in all patient group (HR = 12.232 95%CI: 2.883 to 51.907, p = 0.001) and in group of patients without distant metastasis (HR = 6.744, 95%CI: 1.257 to 36.172, p = 0.026).
Conclusions
CD3+, CD4+ T cell and NK cell percentage in peripheral blood may reflect the the status of distant metastasis in pNET patients. The percentage of peripheral B cells cells may independently predict the progression of pNET patients with or without distant metastasis, making them promising clinical indicators to instruct the frequency for reexaminations after primary medical treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yitao Gong.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract